Molecular diagnostics company Predictive Biosciences has closed a $21.75 million Series B round of financing. New Enterprise Associates and Kaiser Permanente Ventures led the round. The company is developing non-invasive diagnostic products for cancer management and exploring the application of its assays in breast, prostate, ovarian and colorectal cancers. Predictive plans to use the funding to complete current clinical validation studies and initiate multi-center clinical trials. Release